Merck KGaA teams up with Italian oncology group in PARP1 development deal
An Italian group has allied itself with Merck KGaA in an oncology licensing deal, seeking to get in on the market opportunity and expand its reach in a possibly blockbuster market.
Merck KGaA and Italian oncology company Nerviano Medical Sciences jointly announced Wednesday that they are collaborating on a licensing deal for NMS’s PARP1 inhibitor. Called NMS-293, the drug candidate is currently in clinical trials to treat patients as a monotherapy with a specific type of tumor: BRCA-mutated.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.